(MENAFN- PR Newswire)
Delivering on commitments, executing ahead of expectations, and raising guidance
Innovation driving sustained growth across many franchises:
TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation
GALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ --
Medtronic plc (NYSE: MDT ) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024.
Key Highlights
Continue Reading
View PDF
View PDF
Revenue of $8.4 billion increased 5.3% as reported and 5.0% organic
GAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.26
Company raises FY25 organic revenue growth and EPS guidance
Financial Results
Medtronic reported Q2 worldwide revenue of $8.403 billion, an increase of 5.3% as reported and 5.0% on an organic basis. Organic revenue growth comparison excludes:
Other revenue of $37 million in the current year and $61 million in the prior year; and
Foreign currency translation benefit of $45 million on the remaining segments.
As reported, Q2 GAAP net income and diluted earnings per share (EPS) were $1.270 billion and $0.99, respectively, representing increases of 40% and 46%, respectively. As detailed in the financial schedules included at the end of this release, Q2 non-GAAP net income and non-GAAP diluted EPS were $1.620 billion and $1.26, respectively, representing a decrease of 3% and an increase of 1%, respectively. Included in Q2 non-GAAP diluted EPS was a -9 cent impact from foreign currency translation. Non-GAAP adjusted diluted EPS grew 8% on a constant currency basis.
"Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations," said Geoff Martha, Medtronic chairman and chief executive officer. "Innovation matters, and innovation is really driving our growth today. As we look ahead, we're confident that this diversified growth will keep going, especially given the strength of our pipeline in high-impact markets that will allow us to benefit even more patients around the world."
Cardiovascular Portfolio
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Revenue of $3.102 billion increased 6.1% as reported and 5.6% organic, with a high-single digit increase in SHA and mid-single digit increases in CRHF and CPV, all on an organic basis.
CRHF results included mid-single digit growth in Cardiac Rhythm Management, driven by high-single digit growth in Defibrillation Solutions and Cardiac Pacing Therapies, including high-teens growth in MicraTM transcatheter pacing systems; Cardiac Ablation Solutions had flat results as strong growth of the PulseSelectTM pulsed field ablation (PFA) system offset declines in cryoablation
SHA results driven by high-single digit growth in Structural Heart, on the U.S. launch of the EvolutTM FX+ TAVR system, and low-double digit growth in Cardiac Surgery
CPV delivered mid-single digit growth in both Coronary, with strength in guide catheters and balloons, and Peripheral Vascular Health
Ramping commercial availability of the AfferaTM Mapping and Ablation System and Sphere-9TM catheter following late October U.S. Food and Drug Administration (FDA) approval
Received CE Mark for EvolutTM FX+ TAVR system in late October; started commercial launch across Europe this month
Launched Avalus UltraTM surgical valve in Western Europe and VitalFlowTM Extracorporeal Membrane Oxygenation (ECMO) system in the U.S.
In September, SymplicityTM blood pressure procedure named to FORTUNE 2024 'Change the World' list
Earlier this month, granted transitional pass-through (TPT) payment under the U.S. Medicare Hospital Outpatient Prospective Payment System beginning January 1, 2025, for Symplicity SpyralTM renal denervation (RDN) catheter, used in the SymplicityTM blood pressure procedure
Neuroscience Portfolio
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Revenue of $2.451 billion increased 7.1% as reported and 6.7% organic, with a low-double digits increase in Neuromodulation and mid-single digit increases in both CST and Specialty Therapies, all on an organic basis.
CST above market performance driven by continued adoption of the AiBLETM ecosystem of spine implants and enabling technology, with mid-single digit growth in Core Spine and high-single digit growth in Biologics and Neurosurgery
Specialty Therapies results driven by mid-single digit growth in both Neurovascular, with continued strength in hemorrhagic stroke products, and Pelvic Health, on continued adoption of the InterStim XTM system; ENT grew low-single digits on strength in capital placements
Neuromodulation drove above market performance, with high-teens growth in Brain Modulation on the continued launch of the PerceptTM RC deep brain stimulator (DBS) with BrainSenseTM technology; Pain Therapies grew low-double digits, including low-double digit growth in U.S. Pain Stim on the continued launch of the InceptivTM spinal cord stimulator
Medtronic pioneering ADAPT-PD clinical trial methods and preliminary data studying adaptive deep brain stimulation (aDBS) published in September in npj Parkinson's Disease , part of the prestigious Nature Portfolio of journals
In September, expanded AiBLETM spine surgery ecosystem with new technologies and announced partnership with Siemens Healthineers to co-market and integrate the Siemens Healthineers Multitom RaxTM imaging system
Medical Surgical Portfolio
The Medical Surgical Portfolio includes the Surgical & Endoscopy (SE) and the Acute Care & Monitoring (ACM) divisions. Revenue of $2.128 billion increased 1.2% as reported and increased 0.7% organic, with low-single digit organic increase in ACM and flat organic result in SE. SE year-over-year results were affected by a difficult comparison from prior year supply recovery in Surgical and increased high-single digits sequentially.
SE results included flat results in both Advanced Surgical Technologies, with strength in Advanced Energy, driven by continued adoption of the LigaSureTM Maryland XP vessel sealer, offsetting declines in Advanced Stapling; General Surgical Technologies grew low-single digits, with strength in Hernia and Wound Management products
ACM performance included high-single digit growth in NellcorTM Blood Oxygen Management products
Diabetes
Revenue of $686 million increased 12.4% as reported and 11.0% organic.
U.S. revenue grew high-single digits on the continued adoption of the MiniMedTM 780G automated insulin delivery (AID) system
International revenue grew low-double digits on increasing CGM attachment rates and the continued roll-out of Simplera SyncTM sensor
In September, meta-analysis of 28 randomized control trials published in Diabetes/Metabolism Research and Reviews concluded MiniMedTM 780G achieved highest time-in-range among seven commercial AID systems
Guidance
The company today raised its FY25 revenue growth and EPS guidance.
The company raised its FY25 organic revenue growth guidance to 4.75% to 5% versus the prior range of 4.5% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth on an adjusted basis would be in the range of 3.4% to 3.9%.
The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.44 to $5.50 versus the prior $5.42 to $5.50. This includes an estimated -5% impact from foreign currency exchange based on recent rates, unchanged from the prior guidance. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.
"We're restoring our earnings power through our focus on underlying margin improvement, delivering another quarter of high-single digit constant currency adjusted EPS growth," said Gary Corona, Medtronic interim chief financial officer. "And now, as the impact from foreign currency abates, we expect to report high-single digit adjusted EPS growth in the back half of our fiscal year, in line with our long-term commitment to deliver durable, mid-single digit organic revenue growth with EPS leverage."
FY24 Impact Report
Today, Medtronic released its FY24 Impact Report
demonstrating the company's sustainability progress. Medtronic also launched a new Impact webpage
and FY24 Highlights Report
featuring notable key performance indicators and stories, as well as an online Data Hub
that shows the company's commitment to transparent disclosure and reporting:
Achieved 2025 goal to reduce greenhouse gas intensity by 50% a year early, with a 52% reduction in FY24
Exceeded goal to reduce aggregate product complaint rate by 10% for identified product families, with a 33% reduction in FY24
More than 78 million patients served
through expanded access strategies
$2.7B spent in R&D investments to drive innovation
Video Webcast Information
Medtronic will host a video webcast today, November 19, at 8:00 a.m. EST (7:00 a.m. CST) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Events icon at href="" rel="nofollow" medtroni , and this earnings release will be archived at href="" rel="nofollow" medtroni . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Events icon at href="" rel="nofollow" medtroni .
Medtronic plans to report its FY25 third and fourth quarter results on Tuesday, February 18, 2025, and Wednesday, May 21, 2025, respectively. Confirmation and additional details will be provided closer to the specific event.
Financial Schedules and Earnings Presentation
The second quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at href="" rel="nofollow" medtroni . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the first quarter earnings presentation, click here .
| MEDTRONIC PLC WORLD WIDE REVENUE(1) (Unaudited) |
|
|
SECOND QUARTER |
|
|
YEAR-TO-DATE |
|
REPORTED |
|
|
|
ORGANIC |
|
|
REPORTED |
|
|
|
ORGANIC |
| (in millions) |
FY25 |
|
FY24 |
|
Growth |
|
Currency
Impact(3) |
|
Adjusted
FY25(4) |
|
Adjusted
FY24(4) |
|
Growth |
|
|
FY25 |
|
FY24 |
|
Growth |
|
Currency
Impact(3) |
|
Adjusted
FY25(5) |
|
Adjusted
FY24(5) |
|
Growth |
| Cardiovascular |
$
3,102 |
|
$
2,923 |
|
6.1
% |
|
$
16 |
|
$
3,086 |
|
$
2,923 |
|
5.6
% |
|
|
$
6,108 |
|
$
5,773 |
|
5.8
% |
|
$
(23) |
|
$
6,132 |
|
$
5,773 |
|
6.2
% |
| Cardiac Rhythm & Heart Failure |
1,578 |
|
1,492 |
|
5.8 |
|
11 |
|
1,567 |
|
1,492 |
|
5.0 |
|
|
3,114 |
|
2,938 |
|
6.0 |
|
(8) |
|
3,122 |
|
2,938 |
|
6.2 |
| Structural Heart & Aortic |
881 |
|
819 |
|
7.6 |
|
4 |
|
877 |
|
819 |
|
7.1 |
|
|
1,736 |
|
1,633 |
|
6.3 |
|
(8) |
|
1,744 |
|
1,633 |
|
6.8 |
| Coronary & Peripheral Vascular |
643 |
|
613 |
|
4.9 |
|
1 |
|
642 |
|
613 |
|
4.8 |
|
|
1,259 |
|
1,202 |
|
4.7 |
|
(7) |
|
1,266 |
|
1,202 |
|
5.3 |
| Neuroscience |
2,451 |
|
2,288 |
|
7.1 |
|
10 |
|
2,441 |
|
2,288 |
|
6.7 |
|
|
4,768 |
|
4,506 |
|
5.8 |
|
(8) |
|
4,776 |
|
4,506 |
|
6.0 |
| Cranial & Spinal Technologies |
1,234 |
|
1,157 |
|
6.7 |
|
3 |
|
1,231 |
|
1,157 |
|
6.4 |
|
|
2,382 |
|
2,260 |
|
5.4 |
|
(6) |
|
2,387 |
|
2,260 |
|
5.6 |
| Specialty Therapies |
737 |
|
705 |
|
4.6 |
|
5 |
|
732 |
|
705 |
|
3.9 |
|
|
1,450 |
|
1,400 |
|
3.5 |
|
(2) |
|
1,452 |
|
1,400 |
|
3.7 |
| Neuromodulation |
480 |
|
426 |
|
12.6 |
|
2 |
|
478 |
|
426 |
|
12.1 |
|
|
937 |
|
846 |
|
10.8 |
|
(1) |
|
938 |
|
846 |
|
10.9 |
| Medical Surgical |
2,128 |
|
2,103 |
|
1.2 |
|
10 |
|
2,117 |
|
2,103 |
|
0.7 |
|
|
4,123 |
|
4,107 |
|
0.4 |
|
(18) |
|
4,142 |
|
4,107 |
|
0.8 |
| Surgical & Endoscopy |
1,649 |
|
1,641 |
|
0.5 |
|
9 |
|
1,641 |
|
1,641 |
|
- |
|
|
3,193 |
|
3,187 |
|
0.2 |
|
(13) |
|
3,207 |
|
3,187 |
|
0.6 |
| Acute Care & Monitoring |
478 |
|
462 |
|
3.6 |
|
1 |
|
477 |
|
462 |
|
3.3 |
|
|
930 |
|
921 |
|
1.0 |
|
(5) |
|
935 |
|
921 |
|
1.6 |
| Diabetes |
686 |
|
610 |
|
12.4 |
|
9 |
|
678 |
|
610 |
|
11.0 |
|
|
1,333 |
|
1,189 |
|
12.1 |
|
5 |
|
1,329 |
|
1,189 |
|
11.8 |
| Total Reportable Segments |
8,366 |
|
7,923 |
|
5.6 |
|
45 |
|
8,322 |
|
7,923 |
|
5.0 |
|
|
16,333 |
|
15,575 |
|
4.9 |
|
(46) |
|
16,379 |
|
15,575 |
|
5.2 |
| Other(2) |
37 |
|
61 |
|
(38.9) |
|
- |
|
- |
|
- |
|
- |
|
|
(15) |
|
111 |
|
(113.5) |
|
(2) |
|
- |
|
- |
|
- |
| TOTAL |
$
8,403 |
|
$
7,984 |
|
5.3
% |
|
$
45 |
|
$
8,322 |
|
$
7,923 |
|
5.0
% |
|
|
$
16,318 |
|
$
15,686 |
|
4.0
% |
|
$
(48) |
|
$
16,379 |
|
$
15,575 |
|
5.2
% |
|
|
| (1) |
The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| (2) |
Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
| (3) |
The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
| (4) |
The three months ended October 25, 2024 includes $82 million of revenue adjustments related to $37 million of inorganic revenue for the transition activity noted in (2) and $45 million of favorable currency impact on the remaining segments. The three months ended October 27, 2023 excludes $61 million of inorganic revenue related to the transition activity noted in (2). |
| (5) |
The six months ended October 25, 2024 excludes $61 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $75 million of inorganic revenue related to the transition activity noted in (2), and $46 million of unfavorable currency impact on the remaining segments. The six months ended October 27, 2023 excludes $111 million of inorganic revenue related to the transition activity noted in (2). |
| MEDTRONIC PLC U.S.(1)(2) REVENUE (Unaudited) |
|
|
SECOND QUARTER |
|
|
YEAR-TO-DATE |
|
REPORTED |
|
ORGANIC |
|
|
REPORTED |
|
ORGANIC |
| (in millions) |
FY25 |
|
FY24 |
|
Growth |
|
Adjusted
FY25 |
|
Adjusted
FY24 |
|
Growth |
|
|
FY25 |
|
FY24 |
|
Growth |
|
Adjusted
FY25 |
|
Adjusted
FY24 |
|
Growth |
| Cardiovascular |
$
1,434 |
|
$
1,427 |
|
0.5
% |
|
$
1,434 |
|
$
1,427 |
|
0.5
% |
|
|
$
2,836 |
|
$
2,776 |
|
2.2
% |
|
$
2,836 |
|
$
2,776 |
|
2.2
% |
| Cardiac Rhythm & Heart Failure |
768 |
|
782 |
|
(1.8) |
|
768 |
|
782 |
|
(1.8) |
|
|
1,534 |
|
1,502 |
|
2.1 |
|
1,534 |
|
1,502 |
|
2.1 |
| Structural Heart & Aortic |
388 |
|
367 |
|
5.7 |
|
388 |
|
367 |
|
5.7 |
|
|
757 |
|
724 |
|
4.5 |
|
757 |
|
724 |
|
4.5 |
| Coronary & Peripheral Vascular |
278 |
|
278 |
|
0.1 |
|
278 |
|
278 |
|
0.1 |
|
|
546 |
|
550 |
|
(0.8) |
|
546 |
|
550 |
|
(0.8) |
| Neuroscience |
1,677 |
|
1,560 |
|
7.5 |
|
1,677 |
|
1,560 |
|
7.5 |
|
|
3,242 |
|
3,057 |
|
6.0 |
|
3,242 |
|
3,057 |
|
6.0 |
| Cranial & Spinal Technologies |
926 |
|
863 |
|
7.2 |
|
926 |
|
863 |
|
7.2 |
|
|
1,781 |
|
1,685 |
|
5.7 |
|
1,781 |
|
1,685 |
|
5.7 |
| Specialty Therapies |
418 |
|
403 |
|
3.6 |
|
418 |
|
403 |
|
3.6 |
|
|
816 |
|
795 |
|
2.6 |
|
816 |
|
795 |
|
2.6 |
| Neuromodulation |
333 |
|
293 |
|
13.7 |
|
333 |
|
293 |
|
13.7 |
|
|
645 |
|
577 |
|
11.8 |
|
645 |
|
577 |
|
11.8 |
| Medical Surgical |
944 |
|
948 |
|
(0.4) |
|
944 |
|
948 |
|
(0.4) |
|
|
1,825 |
|
1,815 |
|
0.5 |
|
1,825 |
|
1,815 |
|
0.5 |
| Surgical & Endoscopy |
675 |
|
688 |
|
(1.9) |
|
675 |
|
688 |
|
(1.9) |
|
|
1,304 |
|
1,308 |
|
(0.2) |
|
1,304 |
|
1,308 |
|
(0.2) |
| Acute Care & Monitoring |
269 |
|
260 |
|
3.6 |
|
269 |
|
260 |
|
3.6 |
|
|
521 |
|
508 |
|
2.6 |
|
521 |
|
508 |
|
2.6 |
| Diabetes |
232 |
|
217 |
|
6.9 |
|
232 |
|
217 |
|
6.9 |
|
|
447 |
|
405 |
|
10.4 |
|
447 |
|
405 |
|
10.4 |
| Total Reportable Segments |
4,286 |
|
4,151 |
|
3.3 |
|
4,286 |
|
4,151 |
|
3.3 |
|
|
8,350 |
|
8,054 |
|
3.7 |
|
8,350 |
|
8,054 |
|
3.7 |
| Other(3) |
18 |
|
23 |
|
(22.2) |
|
- |
|
- |
|
- |
|
|
37 |
|
45 |
|
(19.0) |
|
- |
|
- |
|
- |
| TOTAL |
$
4,304 |
|
$
4,175 |
|
3.1
% |
|
$
4,286 |
|
$
4,151 |
|
3.3
% |
|
|
$
8,387 |
|
$
8,099 |
|
3.6
% |
|
$
8,350 |
|
$
8,054 |
|
3.7
% |
|
|
| (1) |
U.S. includes the United States and U.S. territories. |
| (2) |
The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| (3) |
Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. |
| MEDTRONIC PLC INTERNATIONAL REVENUE(1) (Unaudited) |
|
|
SECOND QUARTER |
|
|
YEAR-TO-DATE |
|
REPORTED |
|
|
|
ORGANIC |
|
|
REPORTED |
|
|
|
ORGANIC |
| (in millions) |
FY25 |
|
FY24 |
|
Growth |
|
Currency
Impact(3) |
|
Adjusted
FY25(4) |
|
Adjusted
FY24(4) |
|
Growth |
|
|
FY25 |
|
FY24 |
|
Growth |
|
Currency
Impact(3) |
|
Adjusted
FY25(5) |
|
Adjusted
FY24(5) |
|
Growth |
| Cardiovascular |
$
1,668 |
|
$
1,496 |
|
11.5
% |
|
$
16 |
|
$
1,652 |
|
$
1,496 |
|
10.4
% |
|
|
$
3,272 |
|
$
2,996 |
|
9.2
% |
|
$
(23) |
|
$
3,295 |
|
$
2,996 |
|
10.0
% |
| Cardiac Rhythm & Heart Failure |
811 |
|
710 |
|
14.2 |
|
11 |
|
799 |
|
710 |
|
12.6 |
|
|
1,580 |
|
1,436 |
|
10.0 |
|
(8) |
|
1,588 |
|
1,436 |
|
10.6 |
| Structural Heart & Aortic |
492 |
|
451 |
|
9.1 |
|
4 |
|
488 |
|
451 |
|
8.3 |
|
|
980 |
|
909 |
|
7.8 |
|
(8) |
|
988 |
|
909 |
|
8.7 |
| Coronary & Peripheral Vascular |
365 |
|
335 |
|
8.9 |
|
1 |
|
364 |
|
335 |
|
8.7 |
|
|
713 |
|
652 |
|
9.3 |
|
(7) |
|
720 |
|
652 |
|
10.4 |
| Neuroscience |
774 |
|
728 |
|
6.3 |
|
10 |
|
764 |
|
728 |
|
5.0 |
|
|
1,526 |
|
1,449 |
|
5.3 |
|
(8) |
|
1,535 |
|
1,449 |
|
5.9 |
| Cranial & Spinal Technologies |
308 |
|
293 |
|
5.0 |
|
3 |
|
305 |
|
293 |
|
3.9 |
|
|
600 |
|
576 |
|
4.2 |
|
(6) |
|
606 |
|
576 |
|
5.2 |
| Specialty Therapies |
319 |
|
302 |
|
5.8 |
|
5 |
|
315 |
|
302 |
|
4.3 |
|
|
634 |
|
605 |
|
4.8 |
|
(2) |
|
636 |
|
605 |
|
5.1 |
| Neuromodulation |
146 |
|
133 |
|
10.4 |
|
2 |
|
144 |
|
133 |
|
8.8 |
|
|
292 |
|
269 |
|
8.8 |
|
(1) |
|
293 |
|
269 |
|
9.1 |
| Medical Surgical |
1,183 |
|
1,155 |
|
2.5 |
|
10 |
|
1,173 |
|
1,155 |
|
1.6 |
|
|
2,298 |
|
2,292 |
|
0.3 |
|
(18) |
|
2,317 |
|
2,292 |
|
1.1 |
| Surgical & Endoscopy |
974 |
|
953 |
|
2.3 |
|
9 |
|
966 |
|
953 |
|
1.4 |
|
|
1,889 |
|
1,879 |
|
0.5 |
|
(13) |
|
1,902 |
|
1,879 |
|
1.2 |
| Acute Care & Monitoring |
209 |
|
202 |
|
3.5 |
|
1 |
|
208 |
|
202 |
|
2.8 |
|
|
409 |
|
413 |
|
(0.9) |
|
(5) |
|
414 |
|
413 |
|
0.4 |
| Diabetes |
455 |
|
394 |
|
15.5 |
|
9 |
|
446 |
|
394 |
|
13.2 |
|
|
886 |
|
784 |
|
13.1 |
|
5 |
|
882 |
|
784 |
|
12.5 |
| Total Reportable Segments |
4,080 |
|
3,772 |
|
8.2 |
|
45 |
|
4,035 |
|
3,772 |
|
7.0 |
|
|
7,983 |
|
7,521 |
|
6.1 |
|
(46) |
|
8,028 |
|
7,521 |
|
6.7 |
| Other(2) |
19 |
|
37 |
|
(49.4) |
|
- |
|
- |
|
- |
|
- |
|
|
(51) |
|
66 |
|
(178.3) |
|
(2) |
|
- |
|
- |
|
- |
| TOTAL |
$
4,099 |
|
$
3,809 |
|
7.6
% |
|
$
45 |
|
$
4,035 |
|
$
3,772 |
|
7.0
% |
|
|
$
7,931 |
|
$
7,587 |
|
4.5
% |
|
$
(48) |
|
$
8,028 |
|
$
7,521 |
|
6.7
% |
|
|
| (1) |
The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| (2) |
Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested, and specifically for the three months ended July 26, 2024, impacting year-to-date figures, $90 million of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
| (3) |
The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. |
| (4) |
The three months ended October 25, 2024 includes $64 million of revenue adjustments related to $19 million of inorganic revenue for the transition activity noted in (2), and $45 million of favorable currency impact on the remaining segments. The three months ended October 27, 2023 excludes $37 million of inorganic revenue related to the transition activity noted in (2). |
| (5) |
The six months ended October 25, 2024 excludes $97 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2), $38 million of inorganic revenue related to the transition activity noted in (2), and $46 million of unfavorable currency impact on the remaining segments. The six months ended October 27, 2023 excludes $66 million of inorganic revenue related to the transition activity noted in (2). |
| MEDTRONIC PLC CONSOLIDATED STATEMENTS OF INCOME (Unaudited)
|
|
|
Three
months
ended |
|
Six months ended |
| (in millions, except per share data) |
October 25, 2024 |
|
October 27, 2023 |
|
October 25, 2024 |
|
October 27, 2023 |
| Net sales |
$
8,403 |
|
$
7,984 |
|
$
16,318 |
|
$
15,686 |
| Costs and expenses: |
|
|
|
|
|
|
|
| Cost of products sold, excluding amortization of intangible assets |
2,946 |
|
2,761 |
|
5,707 |
|
5,390 |
| Research and development expense |
697 |
|
698 |
|
1,373 |
|
1,365 |
| Selling, general, and administrative expense |
2,757 |
|
2,686 |
|
5,412 |
|
5,299 |
| Amortization of intangible assets |
413 |
|
425 |
|
827 |
|
855 |
| Restructuring charges, net |
30 |
|
40 |
|
77 |
|
94 |
| Certain litigation charges, net |
- |
|
65 |
|
81 |
|
105 |
| Other operating income, net |
(34) |
|
(31) |
|
(33) |
|
(30) |
| Operating profit |
1,595 |
|
1,340 |
|
2,873 |
|
2,608 |
| Other non-operating income, net |
(173) |
|
(154) |
|
(330) |
|
(230) |
| Interest expense, net |
209 |
|
180 |
|
376 |
|
329 |
| Income before income taxes |
1,559 |
|
1,313 |
|
2,827 |
|
2,510 |
| Income tax provision |
281 |
|
402 |
|
500 |
|
802 |
| Net income |
1,278 |
|
911 |
|
2,327 |
|
1,708 |
| Net income attributable to noncontrolling interests |
(9) |
|
(2) |
|
(15) |
|
(8) |
| Net income attributable to Medtronic |
$
1,270 |
|
$
909 |
|
$
2,312 |
|
$
1,700 |
| Basic earnings per share |
$
0.99 |
|
$
0.68 |
|
$
1.79 |
|
$
1.28 |
| Diluted earnings per share |
$
0.99 |
|
$
0.68 |
|
$
1.79 |
|
$
1.28 |
| Basic weighted average shares outstanding |
1,282.4 |
|
1,330.2 |
|
1,288.6 |
|
1,330.3 |
|
|
|
|
|
|
|
|
| Diluted weighted average shares outstanding |
1,286.9 |
|
1,331.9 |
|
1,292.5 |
|
1,332.8 |
|
| The data in the schedule above has been intentionally rounded to the nearest million. |
| MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS(1) (Unaudited)
|
|
|
Three months ended October
25, 2024 |
| (in millions, except per share data) |
Net
Sales |
|
Cost of
Products
Sold |
|
Gross
Margin
Percent |
|
Operating
Profit |
|
Operating
Profit
Percent |
|
Income
Before
Income
Taxes |
|
Net Income
attributable
to
Medtronic |
|
Diluted
EPS |
|
Effective
Tax Rate |
| GAAP |
$
8,403 |
|
$
2,946 |
|
64.9
% |
|
$
1,595 |
|
19.0
% |
|
$
1,559 |
|
$
1,270 |
|
$
0.99 |
|
18.0
% |
| Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
- |
|
- |
|
- |
|
413 |
|
4.9 |
|
413 |
|
338 |
|
0.26 |
|
18.2 |
| Restructuring and associated costs(2) |
- |
|
(11) |
|
0.1 |
|
46 |
|
0.5 |
|
46 |
|
37 |
|
0.03 |
|
19.6 |
| Acquisition and divestiture-related items(3) |
- |
|
(5) |
|
0.1 |
|
(25) |
|
(0.3) |
|
(25) |
|
(30) |
|
(0.02) |
|
(20.0) |
| (Gain)/loss on minority investments(4) |
- |
|
- |
|
- |
|
- |
|
- |
|
(10) |
|
(21) |
|
(0.02) |
|
(100.0) |
| Medical device regulations(5) |
- |
|
(9) |
|
0.1 |
|
12 |
|
0.1 |
|
12 |
|
10 |
|
0.01 |
|
16.7 |
| Certain tax adjustments, net |
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
16 |
|
0.01 |
|
- |
| Non-GAAP |
$
8,403 |
|
$
2,921 |
|
65.2
% |
|
$
2,041 |
|
24.3
% |
|
$
1,995 |
|
$
1,620 |
|
$
1.26 |
|
18.3
% |
| Currency impact |
(45) |
|
(103) |
|
1.1 |
|
145 |
|
1.9 |
|
|
|
|
|
0.09 |
|
|
| Currency Adjusted |
$
8,358 |
|
$
2,818 |
|
66.3
% |
|
$
2,186 |
|
26.2
% |
|
|
|
|
|
$
1.35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended October
27, 2023 |
| (in millions, except per share data) |
Net
Sales |
|
Cost of
Products
Sold |
|
Gross
Margin
Percent |
|
Operating
Profit |
|
Operating
Profit
Percent |
|
Income
Before
Income
Taxes |
|
Net Income
attributable
to
Medtronic |
|
Diluted
EPS |
|
Effective
Tax Rate |
| GAAP |
$
7,984 |
|
$
2,761 |
|
65.4
% |
|
$
1,340 |
|
16.8
% |
|
$
1,313 |
|
$
909 |
|
$
0.68 |
|
30.6
% |
| Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
- |
|
- |
|
- |
|
425 |
|
5.3 |
|
425 |
|
360 |
|
0.27 |
|
15.3 |
| Restructuring and associated costs(2) |
- |
|
(15) |
|
0.2 |
|
91 |
|
1.1 |
|
91 |
|
76 |
|
0.06 |
|
17.6 |
| Acquisition and divestiture-related items(3) |
- |
|
(6) |
|
0.1 |
|
58 |
|
0.7 |
|
58 |
|
51 |
|
0.04 |
|
12.1 |
| Certain litigation charges, net |
- |
|
- |
|
- |
|
65 |
|
0.8 |
|
65 |
|
50 |
|
0.04 |
|
23.1 |
| (Gain)/loss on minority investments(4) |
- |
|
- |
|
- |
|
- |
|
- |
|
25 |
|
21 |
|
0.02 |
|
20.0 |
| Medical device regulations(5) |
- |
|
(21) |
|
0.3 |
|
30 |
|
0.4 |
|
30 |
|
24 |
|
0.02 |
|
20.0 |
| Certain tax adjustments, net(6) |
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
176 |
|
0.13 |
|
- |
| Non-GAAP |
$
7,984 |
|
$
2,720 |
|
65.9
% |
|
$
2,009 |
|
25.2
% |
|
$
2,008 |
|
$
1,667 |
|
$
1.25 |
|
16.9
% |
|
|
| See description of non-GAAP financial measures contained in the press release dated November 19, 2024. |
| (1) |
The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
| (2) |
Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
| (3) |
The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The three months ended October 25, 2024, also include gains related to certain business or asset sales. |
| (4) |
We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
| (5) |
The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
| (6) |
The charge primarily relates to the establishment of a valuation allowance against certain net operating losses. |
| MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS(1) (Unaudited)
|
|
|
Six months ended October 25, 2024 |
| (in millions, except per share data) |
Net
Sales |
|
Cost of
Products
Sold |
|
Gross
Margin
Percent |
|
Operating
Profit |
|
Operating
Profit
Percent |
|
Income
Before
Income
Taxes |
|
Net Income
attributable
to
Medtronic |
|
Diluted
EPS |
|
Effective
Tax Rate |
| GAAP |
$ 16,318 |
|
$
5,707 |
|
65.0
% |
|
$
2,873 |
|
17.6
% |
|
$
2,827 |
|
$
2,312 |
|
$
1.79 |
|
17.7
% |
| Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
- |
|
- |
|
- |
|
827 |
|
4.9 |
|
827 |
|
678 |
|
0.52 |
|
18.0 |
| Restructuring and associated costs(2) |
- |
|
(20) |
|
0.1 |
|
108 |
|
0.6 |
|
108 |
|
87 |
|
0.07 |
|
19.4 |
| Acquisition and divestiture-related items(3) |
- |
|
(16) |
|
0.1 |
|
(13) |
|
(0.1) |
|
(13) |
|
(19) |
|
(0.01) |
|
(46.2) |
| Certain litigation charges, net |
- |
|
- |
|
- |
|
81 |
|
0.5 |
|
81 |
|
68 |
|
0.05 |
|
16.0 |
| (Gain)/loss on minority investments(4) |
- |
|
- |
|
- |
|
- |
|
- |
|
(27) |
|
(38) |
|
(0.03) |
|
(37.0) |
| Medical device regulations(5) |
- |
|
(20) |
|
0.1 |
|
27 |
|
0.2 |
|
27 |
|
22 |
|
0.02 |
|
18.5 |
| Other(6) |
90 |
|
- |
|
0.4 |
|
90 |
|
0.5 |
|
90 |
|
70 |
|
0.05 |
|
22.2 |
| Certain tax adjustments, net |
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
33 |
|
0.03 |
|
- |
| Non-GAAP |
$ 16,408 |
|
$
5,651 |
|
65.6
% |
|
$
3,993 |
|
24.3
% |
|
$
3,921 |
|
$
3,213 |
|
$
2.49 |
|
17.7
% |
| Currency impact |
46 |
|
(134) |
|
0.9 |
|
246 |
|
1.5 |
|
|
|
|
|
0.16 |
|
|
| Currency Adjusted |
$ 16,454 |
|
$
5,517 |
|
66.5
% |
|
$
4,239 |
|
25.8
% |
|
|
|
|
|
$
2.65 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended October 27, 2023 |
| (in millions, except per share data) |
Net
Sales |
|
Cost of
Products
Sold |
|
Gross
Margin
Percent |
|
Operating
Profit |
|
Operating
Profit
Percent |
|
Income
Before
Income
Taxes |
|
Net Income
attributable
to
Medtronic |
|
Diluted
EPS |
|
Effective
Tax Rate |
| GAAP |
$ 15,686 |
|
$
5,390 |
|
65.6
% |
|
$
2,608 |
|
16.6
% |
|
$
2,510 |
|
$
1,700 |
|
$
1.28 |
|
32.0
% |
| Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of intangible assets |
- |
|
- |
|
- |
|
855 |
|
5.5 |
|
855 |
|
724 |
|
0.54 |
|
15.2 |
| Restructuring and associated costs(2) |
- |
|
(30) |
|
0.2 |
|
182 |
|
1.2 |
|
182 |
|
152 |
|
0.11 |
|
16.5 |
| Acquisition and divestiture-related items(3) |
- |
|
(12) |
|
0.1 |
|
107 |
|
0.7 |
|
107 |
|
97 |
|
0.07 |
|
9.3 |
| Certain litigation charges, net |
- |
|
- |
|
- |
|
105 |
|
0.7 |
|
105 |
|
81 |
|
0.06 |
|
22.9 |
| (Gain)/loss on minority investments(4) |
- |
|
- |
|
- |
|
- |
|
- |
|
89 |
|
85 |
|
0.06 |
|
5.6 |
| Medical device regulations(5) |
- |
|
(42) |
|
0.3 |
|
62 |
|
0.4 |
|
62 |
|
49 |
|
0.04 |
|
21.0 |
| Certain tax adjustments, net(7) |
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
375 |
|
0.28 |
|
- |
| Non-GAAP |
$ 15,686 |
|
$
5,306 |
|
66.2
% |
|
$
3,919 |
|
25.0
% |
|
$
3,910 |
|
$
3,262 |
|
$
2.45 |
|
16.4
% |
|
|
| See description of non-GAAP financial measures contained in the press release dated November 19, 2024. |
| (1) |
The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. |
| (2) |
Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
| (3) |
The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The six months ended October 25, 2024, also include gains related to certain business or asset sales. |
| (4) |
We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
| (5) |
The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
| (6) |
Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
| (7) |
The charge relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision, the establishment of a valuation allowance against certain net operating losses and amortization of previously established deferred tax assets from intercompany intellectual property transactions. |
| MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS(1) (Unaudited)
|
|
|
Three months ended October
25, 2024 |
| (in millions) |
Net
Sales |
|
SG&A
Expense |
|
SG&A
Expense as
a % of Net
Sales |
|
R&D
Expense |
|
R&D
Expense
as a % of
Net Sales |
|
Other
Operating
(Income)
Expense,
net |
|
Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales |
|
Other Non-
Operating
Income, net |
| GAAP |
$
8,403 |
|
$
2,757 |
|
32.8
% |
|
$
697 |
|
8.3
% |
|
$
(34) |
|
(0.4)
% |
|
$
(173) |
| Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restructuring and associated costs(2) |
- |
|
(6) |
|
(0.1) |
|
- |
|
- |
|
- |
|
- |
|
- |
| Acquisition and divestiture-related items(3) |
- |
|
(19) |
|
(0.2) |
|
- |
|
- |
|
50 |
|
0.6 |
|
- |
| Medical device regulations(4) |
- |
|
- |
|
- |
|
(4) |
|
- |
|
- |
|
- |
|
- |
| (Gain)/loss on minority investments(5) |
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
10 |
| Non-GAAP |
$
8,403 |
|
$
2,732 |
|
32.5
% |
|
$
693 |
|
8.2
% |
|
$
16 |
|
0.2
% |
|
$
(163) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six months ended October
25, 2024 |
| (in millions) |
Net
Sales |
|
SG&A
Expense |
|
SG&A
Expense as
a % of Net
Sales |
|
R&D
Expense |
|
R&D
Expense
as a % of
Net Sales |
|
Other
Operating
(Income)
Expense,
net |
|
Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales |
|
Other Non-
Operating
Income, net |
| GAAP |
$
16,318 |
|
$
5,412 |
|
33.2
% |
|
$
1,373 |
|
8.4
% |
|
$
(33) |
|
(0.2)
% |
|
$
(330) |
| Non-GAAP Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restructuring and associated costs(2) |
- |
|
(11) |
|
(0.1) |
|
- |
|
- |
|
- |
|
- |
|
- |
| Acquisition and divestiture-related items(3) |
- |
|
(27) |
|
(0.3) |
|
- |
|
- |
|
55 |
|
0.3 |
|
- |
| Medical device regulations(4) |
- |
|
- |
|
- |
|
(7) |
|
(0.1) |
|
- |
|
- |
|
- |
| Other(6) |
90 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
| (Gain)/loss on minority investments(5) |
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
27 |
| Non-GAAP |
$
16,408 |
|
$
5,374 |
|
32.8
% |
|
$
1,366 |
|
8.3
% |
|
$
23 |
|
0.1
% |
|
$
(303) |
| See description of non-GAAP financial measures contained in the press release dated November 19, 2024. |
| (1) |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
| (2) |
Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. |
| (3) |
The charges primarily include business combination costs, changes in fair value of contingent consideration, exit of business-related charges, and gains related to certain business or asset sales. |
| (4) |
The charges represent incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. |
| (5) |
We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. |
| (6) |
Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. |
| MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS(1) (Unaudited) |
|
|
Six months ended |
| (in millions) |
October 25, 2024 |
|
October 27, 2023 |
| Net cash provided by operating activities |
$
1,944 |
|
$
1,536 |
| Additions to property, plant, and equipment |
(924) |
|
(815) |
| Free Cash Flow(2) |
$
1,020 |
|
$
721 |
|
|
| See description of non-GAAP financial measures contained in the press release dated November 19, 2024. |
| (1) |
The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
| (2) |
Free cash flow represents operating cash flows less property, plant, and equipment additions. |
| MEDTRONIC PLC CONSOLIDATED BALANCE SHEETS (Unaudited)
|
|
| (in
millions) |
|
October 25, 2024 |
|
April 26, 2024 |
| ASSETS |
|
|
|
|
| Current assets: |
|
|
|
|
| Cash and cash equivalents |
|
$
1,394 |
|
$
1,284 |
| Investments |
|
6,595 |
|
6,721 |
| Accounts receivable, less allowances and credit losses of $195 and $173, respectively |
|
6,260 |
|
6,128 |
| Inventories |
|
5,479 |
|
5,217 |
| Other current assets |
|
2,710 |
|
2,584 |
| Total current assets |
|
22,438 |
|
21,935 |
| Property, plant, and equipment, net |
|
6,438 |
|
6,131 |
| Goodwill |
|
41,161 |
|
40,986 |
| Other intangible assets, net |
|
12,423 |
|
13,225 |
| Tax assets |
|
3,572 |
|
3,657 |
| Other assets |
|
4,009 |
|
4,047 |
| Total assets |
|
$
90,042 |
|
$
89,981 |
| LIABILITIES AND EQUITY |
|
|
|
|
| Current liabilities: |
|
|
|
|
| Current debt obligations |
|
$
3,719 |
|
$
1,092 |
| Accounts payable |
|
2,376 |
|
2,410 |
| Accrued compensation |
|
1,893 |
|
2,375 |
| Accrued income taxes |
|
947 |
|
1,330 |
| Other accrued expenses |
|
3,260 |
|
3,582 |
| Total current liabilities |
|
12,195 |
|
10,789 |
| Long-term debt |
|
24,607 |
|
23,932 |
| Accrued compensation and retirement benefits |
|
1,084 |
|
1,101 |
| Accrued income taxes |
|
1,432 |
|
1,859 |
| Deferred tax liabilities |
|
473 |
|
515 |
| Other liabilities |
|
1,534 |
|
1,365 |
| Total liabilities |
|
41,326 |
|
39,561 |
| Commitments and contingencies |
|
|
|
|
| Shareholders' equity: |
|
|
|
|
| Ordinary shares- par value $0.0001, 2.6 billion shares authorized, 1,282,553,150 and
1,311,337,531 shares issued and outstanding, respectively |
|
- |
|
- |
| Additional paid-in capital |
|
20,824 |
|
23,129 |
| Retained earnings |
|
30,919 |
|
30,403 |
| Accumulated other comprehensive loss |
|
(3,250) |
|
(3,318) |
| Total shareholders' equity |
|
48,494 |
|
50,214 |
| Noncontrolling interests |
|
222 |
|
206 |
| Total equity |
|
48,716 |
|
50,420 |
| Total liabilities and equity |
|
$
90,042 |
|
$
89,981 |
|
| The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
| MEDTRONIC PLC CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) |
|
|
Six months ended |
| (in millions) |
October 25, 2024 |
|
October 27, 2023 |
| Operating Activities: |
|
|
|
| Net income |
$
2,327 |
|
$
1,708 |
| Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
Depreciation and amortization
|
1,337 |
|
1,344 |
|
Provision for credit losses
|
45 |
|
37 |
|
Deferred income taxes
|
57 |
|
(36) |
|
Stock-based compensation
|
242 |
|
219 |
|
Other, net
|
(98) |
|
182 |
|
Change in operating assets and liabilities, net of acquisitions and divestitures:
|
|
|
|
| Accounts receivable, net |
(181) |
|
(117) |
| Inventories |
(278) |
|
(616) |
| Accounts payable and accrued liabilities |
(707) |
|
(699) |
| Other operating assets and liabilities |
(800) |
|
(486) |
| Net cash provided by operating activities |
1,944 |
|
1,536 |
| Investing Activities: |
|
|
|
| Acquisitions, net of cash acquired |
- |
|
(22) |
| Additions to property, plant, and equipment |
(924) |
|
(815) |
| Purchases of investments |
(4,019) |
|
(3,403) |
| Sales and maturities of investments |
4,338 |
|
3,336 |
| Other investing activities, net |
1 |
|
(59) |
| Net cash used in investing activities |
(604) |
|
(963) |
| Financing Activities: |
|
|
|
| Change in current debt obligations, net |
(67) |
|
1,321 |
| Issuance of long-term debt |
3,209 |
|
- |
| Dividends to shareholders |
(1,795) |
|
(1,836) |
| Issuance of ordinary shares |
232 |
|
149 |
| Repurchase of ordinary shares |
(2,780) |
|
(378) |
| Other financing activities, net |
(64) |
|
153 |
| Net cash used in financing activities |
(1,265) |
|
(591) |
| Effect of exchange rate changes on cash and cash equivalents |
35 |
|
(214) |
| Net change in cash and cash equivalents |
110 |
|
(232) |
| Cash and cash equivalents at beginning of period |
1,284 |
|
1,543 |
| Cash and cash equivalents at end of period |
$
1,394 |
|
$
1,311 |
|
|
|
|
| Supplemental Cash Flow Information |
|
|
|
| Cash paid for: |
|
|
|
|
Income taxes
|
$
1,335 |
|
$
1,110 |
|
Interest
|
513 |
|
476 |
|
| The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. |
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT ), visit and follow on LinkedIn .
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.
NON-GAAP FINANCIAL MEASURES
This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2024, and references to sequential changes are in comparison to the prior fiscal quarter.
Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.
Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.
Multitom RaxTM is a trademark of Siemens Healthcare GmbH.
| Contacts: |
|
|
|
| Erika
Winkels
|
Ryan Weispfenning |
| Public Relations
|
Investor Relations |
| +1-763-526-8478
|
+1-763-505-4626 |
SOURCE Medtronic plc
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN19112024003732001241ID1108901425
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.